Camilla and Marc

Brands Collection · High Fashion

Camilla and Marc

Sydney ready-to-wear maison founded 2003 by brother-and-sister duo Camilla Freeman-Topper and Marc Freeman — the architectural-minimalist Australian house whose tailored separates and 'Camilla and Marc for OCRF' breast-cancer-research advocacy anchor the contemporary AU corporate wardrobe.

Camilla and Marc is an Australian fashion house based in Sydney, making ready-to-wear alongside leather goods, footwear, accessories and jewellery. Siblings Camilla Freeman-Topper and Marc Freeman founded it in 2003.

Camilla, the house's Creative Director, trained in fashion design at Sydney's Whitehouse Institute of Design, then won a scholarship to complete a Masters of Fashion Design at the Accademia Italiana Arte Moda in Florence. Marc studied engineering and commerce at the University of New South Wales and brings an analytical, commercial perspective as chief executive.

The clothing centres on tailored and sculptural silhouettes, with clean lines, strong proportions and small unexpected details. Ready-to-wear covers dresses, denim, blazers and suiting, trench coats, knitwear and tracksuits. Tailoring includes the Mackinley Blazer, the Mackinley Double Breasted Blazer and the Mackinley Slim Leg Pant, while the Elaris Lace Bodysuit is made in lace. Shoes, bags, belts, hats, sunglasses and scarves complete the accessories.

The label launched at Australian Fashion Week in 2003 after an invitation to show a first collection, while Camilla was still studying in Florence. In 2009 the pair opened their first standalone store in Paddington, Sydney. The house sells through its own stores across Australia and through wholesale in New Zealand, the UK, France, Germany, the United Arab Emirates and the United States.

The house also runs Ovaries. Talk About Them., a fundraising campaign for ovarian cancer research. The founders were 11 and 13 when their mother, Pamela, died of the disease at 42. Proceeds go to the UNSW Gynaecological Cancer Research Group, where Professor Caroline Ford and Dr Kristina Warton work toward a DNA based early detection test.